Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics ready to test 'entourage effect' hypothesis in cancer research

Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) executive chairman Harry Karelis tells Proactive Investors the medical cannabis researcher's latest news.

Initial results from a paediatric brain cancer study being conducted with the Telethon Kids Institute in Perth have validated that two chemicals naturally occurring in the cannabis plant, THC and CBD, each have some anti-cancer effects. Zelda Therapeutics will now aim to enhance that anti-cancer response by testing various chemical formulations.

“Cannabis seems to be quite a versatile therapeutic. It can treat a range of conditions, but it’s not the same cannabis for every condition; it’s this interplay between these THC and CBD molecules… taking the plant as our platform and then knowing how to mix and match these cannabinoids - what ratios, how much, how to give it, went to give it - means that we can target a whole range of indications from cancer to autism… The next phase in this brain cancer research is really comparing the results from our whole plant extracts versus the pure THC and pure CBD results which we announced,” Karelis explains.

“We’ve alluded to a pipeline of new opportunities that are coming through, and we’re reasonably close to finalising a new research program in a fairly important medical area, and we’re looking forward to finalising that in the coming weeks,” teases Karelis.

A new managing director, Dr Richard Hopkins, will be joining the team in July.

Join our Crypto, Blockchain and Cannabis Telegram group here  
Meet Arix Bioscience Plc, Avacta Group Plc and Silence Therapeutics plc at our event, London , 04 October 2018. Register here »
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use